Answers are grounded in this paper and cite their sources.
A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188-201.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: